U.S. Electrotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the u.S. electrotherapy market size is expected to increase from USD 0.41 billion in 2025 to USD 0.43 billion in 2026 and reach USD 0.56 billion by 2031, growing at a CAGR of 5.20% over 2026-2031.

This report is Segmented by Therapy Type (TENS, IFT, NMES/FES, and More), Application (Pain Management, Neuromuscular Dysfunction, and More), End User (Hospitals, Pain Clinics, PT Centers, Ascs, and More), and Prescription Type (Prescription, OTC, and Hybrid Direct-To-Home). The Market Forecasts are Provided in Terms of Value (USD).

U.S. Electrotherapy Market Trends and Insights

Chronic Pain Burden and Aging-Related Pain Incidence

Chronic pain remains a significant driver for the United States electrotherapy market, with 24.3% of adults, approximately 60 million people, experiencing chronic pain in 2025. Among them, 8.9% faced high-impact chronic pain that disrupted daily activities. Older adults were most affected, with a 36.0% prevalence among those aged 65 and above, compared to 12.3% to 28.7% in younger groups. Conditions like osteoarthritis and spinal degeneration highlight the role of electrotherapy in drug-sparing pain management. The market benefits from a stable demand base across outpatient rehabilitation, homecare, and chronic disease management settings.

Opioid-Sparing Treatment Preference Across Pain Care Pathways

The shift toward non-opioid pain treatments is strengthening the United States electrotherapy market across hospitals, outpatient facilities, and specialist channels. The NOPAIN Act supports Medicare payments for non-opioid treatments through 2027, enhancing the financial case for device-based pain management. The Alternatives to PAIN Act reduces prior authorization barriers under Medicare Part D, favoring non-drug therapies. Specialist endorsements for peripheral nerve stimulation in chronic back pain further drive adoption, with higher-value prescription systems gaining traction over consumer devices.

Reimbursement Friction, Prior Authorization, and LCD Limits

Reimbursement complexities remain a key short-term challenge for the United States electrotherapy market. The WISeR Model, effective January 1, 2026, in states like Arizona, New Jersey, and Texas, introduces AI-assisted prior authorization for electrical nerve stimulators, increasing operational burdens and extending sales cycles. Stricter compliance requirements, such as the CMS LCD L33802 for TENS implemented in January 2024, have already added to suppliers' challenges. Larger manufacturers manage these changes more effectively due to scale and resources, while smaller suppliers face significant administrative hurdles. Texas, a critical Medicare-heavy market, amplifies the revenue impact of these added reviews.

Other drivers and restraints analyzed in the detailed report include:

1. Home-Based Rehabilitation and Portable Device Adoption
2. Higher Outpatient Musculoskeletal and Post-Surgical Rehab Volume
3. Mixed Clinical Evidence Across Some Indications and Modalities

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, TENS therapy devices held a 32.55% share of the therapy type mix, leading the United States electrotherapy market. Their dominance was driven by broad availability across prescription and over-the-counter channels, enhancing access through clinics, pharmacies, retail outlets, and direct purchases. The FDA's 510(k) pathway remained active, with clearances like the OTC 4-Channel Rechargeable TENS Unit and Zynex Medical's TensWave expanding the prescription TENS portfolio. Interferential and microcurrent therapies retained their roles in physiotherapy, while PENS and bone growth stimulation remained specialized.

Neuromuscular electrical stimulation (NMES) is projected to grow at a 6.80% CAGR through 2031, making it the fastest-growing therapy type. Its adoption is increasing in stroke rehabilitation, spinal cord injury recovery, and post-surgical muscle re-education, supported by home-use clearances. High-value implantables like spinal cord stimulation and sacral neuromodulation continue to dominate revenue, while surface devices drive higher unit sales.

Pain management accounted for 42.88% of the application mix in 2025, leading the United States electrotherapy market. This reflects the concentration of prescription TENS, peripheral nerve stimulation, and spinal cord stimulation in outpatient pain clinics and spine practices. Bone healing and spinal fusion support maintained stable demand, driven by clinical necessity in high-risk cases, while wound care and dermatological applications remained limited due to reimbursement challenges.

The market for neuromuscular dysfunction and rehabilitation is forecast to grow at a 6.35% CAGR through 2031, driven by rising incidences of stroke, spinal cord injuries, and traumatic brain injuries. Boston Scientific's acquisition of Axonics strengthened its position in pelvic dysfunction therapy, adding a high-growth segment to the application mix. Pain management remains the anchor, while rehabilitation and pelvic neuromodulation are gaining traction.

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Axonics, Inc.
3. BioWave Corporation
4. Boston Scientific
5. BTL Industries, Inc.
6. DJO Global
7. Electronic Waveform Lab, Inc. (H-Wave)
8. EMS Physio Ltd.
9. Enovis Corporation
10. Gymna Group NV
11. Medtronic
12. Mettler Electronics
13. NeuroMetrix
14. OMRON Healthcare, Inc.
15. Orthofix
16. Richmar
17. RS Medical, Inc.
18. TensCare Ltd.
19. Utah Medical Products
20. Zynex, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support